A recently published paper addressed the interesting topic of prevention of erectile dysfunction (ED) with tadalafil, a phosphodiesterase-type 5 inhibitor (PDE5i) in patients undergoing radiation therapy for localized prostate cancer.
[1] Tadalafil 5 mg or placebo was administered once-daily for 24 weeks in patients undergoing external-beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer. This randomized trial did not show superior efficacy of the active drug compared with placebo 4-6 weeks after stopping the study drug. Furthermore, patients younger than 65 years did not respond significantly better than older patients.
Written by:
Incrocci L. Are you the author?
Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, 3000 CA, The Netherlands.
Reference: Asian J Androl. 2014 Jun 20. Epub ahead of print.
doi: 10.4103/1008-682X.133324
PubMed Abstract
PMID: 24969064
UroToday.com Erectile Dysfunction Section
